MedPath

I Change Adherence & Raise Expectations

Phase 3
Completed
Conditions
Cystic Fibrosis
Interventions
Behavioral: Comprehensive Adherence Program (CAP)
Registration Number
NCT01232478
Lead Sponsor
Johns Hopkins University
Brief Summary

The iCARE study, a clustered-randomized controlled trial, is evaluating an adherence promotion intervention for adolescents that Cystic Fibrosis (CF) care teams will implement. Half the centers will receive the Comprehensive Adherence Program (CAP) for 2 years. CAP consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention). The other half of the centers will receive CAP in year 2 of the study. Participants are patients age 11-20 years old who are diagnosed with CF and have been prescribed at least one of the following medications for at least 6 months prior to signing the informed consent: azithromycin, hypertonic saline, Pulmozyme®, TOBI®, or inhaled compounded tobramycin. Rate of refilling prescriptions is the primary outcome with lung function decline rates, exacerbation rates, and patient reported measures including health related quality of life and CF knowledge and skills, as secondary outcomes.

A central goal of this study is to test the effectiveness of the comprehensive adherence program (CAP), described above, versus standard care (SC) for adolescents and young adults seen in outpatient CF clinics.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
641
Inclusion Criteria
  • Male or female patients age 11 - 20 years old
  • Patients with a diagnosis of CF
  • Patients attend the accredited care center for regularly scheduled clinic visits
  • Patient must be prescribed at least one of the following medications for at least 6 months prior to signing the informed consent:

Azithromycin Hypertonic saline Pulmozyme® TOBI® Inhaled compounded tobramycin

-Patient has consented to provide data to the CF Foundation Registry prior to conversion to PORTCFv2

Exclusion Criteria
  • Patient is planning to change care teams within the next 2 years
  • Patient is seen at a satellite clinic
  • Patient is on the lung transplant list (Note: participation in this study will not delay or exclude patient from being placed on the transplant list in the future or receiving a transplant once enrolled in the study)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Comprehensive Adherence Program (CAP)Comprehensive Adherence Program (CAP)The comprehensive adherence program emphasizes the patient's active, collaborative role in identifying adherence barriers and solving them to improve adherence to prescribed treatment regimens. Problem-solving sessions will be used to address barriers to adherence that are identified by the adolescent. The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re-instruction/re-training of skills needed to perform daily treatments.
Standard Care (SC)Comprehensive Adherence Program (CAP)Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
Primary Outcome Measures
NameTimeMethod
Medication Adherence12 Months

Medication Possession Ratio (MPR) derived from pharmacy refill records

Secondary Outcome Measures
NameTimeMethod
CF knowledge24 Months
Skills associated with CF treatments24 Months
Lung Function24 Months

Forced expiratory volume in one second (FEV1) percent predicted (abstracted from CF registry)

Health Related Quality of Life (HRQOL)24 Months

Cystic Fibrosis Questionnaire- Revised

Pulmonary exacerbation24 months

IV antibiotic treatment (abstracted from CF registry)

CF hospitalizations24 Months

Clinic report of pulmonary hospitalization (abstracted from CF registry)

Trial Locations

Locations (18)

Maine Medical Center

🇺🇸

Portland, Maine, United States

Akron Children's Hospital

🇺🇸

Akron, Ohio, United States

West Virginia University

🇺🇸

Morgantown, West Virginia, United States

Riley Hospital for Children

🇺🇸

Indianapolis, Indiana, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

UAB/CHS Cystic Fibrosis Center

🇺🇸

Birmingham, Alabama, United States

Primary Children's Medical Center

🇺🇸

Salt Lake City, Utah, United States

Connecticut Children's Medical Center

🇺🇸

Hartford, Connecticut, United States

Phoenix Children's Hospital

🇺🇸

Phoenix, Arizona, United States

Children's Memorial Hospital

🇺🇸

Chicago, Illinois, United States

Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

Women and Children's Hospital of Buffalo

🇺🇸

Buffalo, New York, United States

Seattle Children's Hospital

🇺🇸

Seattle, Washington, United States

Toledo Children's Hospital

🇺🇸

Toledo, Ohio, United States

Rainbow Babies and Children's Hospital

🇺🇸

Cleveland, Ohio, United States

University of Rochester Medical Center

🇺🇸

Rochester, New York, United States

Children's Hospital Boston

🇺🇸

Boston, Massachusetts, United States

University of Michigan Health System

🇺🇸

Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath